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Summary The clinical and immune modulatory effects of interleukin-2 (IL-2) and interferon (INF) alfa-2a
were examined in a phase II study in patients with metastatic renal cell carcinoma (six patients) and melanoma
(eight patients). Treatment consisted in IL-2 3 MU/m2 continuous infusion days 1-4 and INF alfa-2a
6 MU/m2 subcutaneously day 1 and 4, both given on alternate weeks. Tumour response was assessed after
four cycles of treatment or earlier, if necessary. Patients with stable disease or response were to be continued
for another nine cycles or up to disease progression. The 14 patients received a total of 60 cycles of treatment.
Major toxicities (WHO Grade III/IV) were fever, capillary leak syndrome with hypotension, nausea and
vomiting, erythema with pruritus, leuco- and thrombopenia and sepsis with staphylococcus aureus. Five of 14
patients (36%) developed a self limiting autoimmune thyroiditis with HLA-DR expression on thyrocytes. Long
term treatment toxicity was moderate with an average weight loss of 5% and an average fall in Karnofsky
index of 10% compared to baseline. No responses were seen in renal cell carcinoma, two patients with
melanoma had a partial and two a minor response with a duration of 1-7 months. Serial measurements of
immune modulatory parameters showed a functional response to treatment with an increase of NK- and
LAK-activity during the first two cycles, followed by a plateau and decrease during the third and fourth
cycles. These findings were paralleled by a successive decline in treatment induced INF gamma response. These
findings suggest, that alternative weekly treatment with IL-2 and INF alfa-2a results in an exhaustion of lytic
capacity of NK- and LAK-cells and an attenuation of secondary cytokine release.
Interleukin-2 (IL-2), a glycosylated polypeptide, was first de-
scribed more than 10 years ago as T-cell growth factor in the
supernatant of cultured lectin stimulated lymphocytes (Mor-
gan et al., 1978). In 1983 the production of recombinant IL-2
became possible (Taniguchi et al., 1983) and since then IL-2
has become widely available for use in clinical studies. IL-2
induces a heterogeneous population of T-lymphocytes
(lymphokine-activated killer cells or LAK-cells) which act
independently of MHC class I antigens and are able to lyse
fresh tumour cells without prior antigen exposition (Grimm
et al., 1983), activates T-cells to produce antigen specific
cytolytic and antiproliferative responses against tumour cells
(Smith, 1988), and induces the release of secondary cytokines
such as interferon (INF) gamma and tumour necrosis factor
(TNF) alfa from activated T-cells and macrophages (Stotter
et al., 1989).
INF alpha, a product of leucocytes, was initially identified
through its antiviral activity (Isaacs & Lindenmann, 1957).
INF alpha also has antitumour activity, either by direct
antiproliferative effects on tumour cells (Fidler et al., 1987),
or indirectly by the induction of MHC class I or tumour
associated antigens on tumour cells (Brunda et al., 1987).
The therapeutic potential of both IL-2 and INF alpha as
single agents has been studied in renal cell carcinoma and
melanoma. Published clinical trials of INF alpha have re-
ported response rates between 10-17% in renal cell car-
cinoma and melanoma (Hersey et al., 1985; Quesada et al.,
1985). Phase II studies of IL-2 with or without LAK cells
have reported tumour responses of 16-31% in renal cell
carcinoma and 14-26% in melanoma (Rosenberg et al.,
1988; Fischer et al., 1988; Stahel et al., 1989; Dutcher et al.,
1989; Bar et al., 1990), although at the cost of considerable
acute toxicity.
With the aim to increase tumour response and/or reduce
IL-2 induced toxicity, clinical studies are currently under way
using IL-2 in combination with other cytokines or with
cytostatic agents. Our decision to study IL-2 and INF alfa-2a
was based on three factors: (1) Either agent alone has
antitumour activity against melanoma or renal cell car-
cinoma, (2) in combination, these two agents have a synergis-
tic antitumour effect in the mouse model (Brunda et al.,
1987) and (3) INF alfa-2a enhances the MHC class I and
tumour associated antigen expression on the cell surface of
tumour cells (Borden et al., 1988) and thus may render them
more susceptible for IL-2 induced cellular cytotoxicity.
We report here the clinical and immune modulatory effects
of alternative weekly continuous infusion IL-2 and sub-
cutaneous INF alfa-2a in 14 patients with renal cell car-
cinoma or melanoma, treated as part of a multicentre trial.
Our findings suggest, that alternative weekly treatment at
doses used here, results in an exhaustion of the lytic capacity
of peripheral blood lymphocytes and an attenuation of
secondary cytokine release.
Materials and methods
Patient selection
Eight patients with metastatic melanoma and six patients
with advanced renal cell carcinoma were treated as part of a
multicentre trial between December 1988 and October 1989.
Selection criteria were measurable disease, prior nephrectomy
in patients with renal cell carcinoma, no chemotherapy, hor-
monal therapy or radiotherapy within 4 weeks prior to study
entry and no prior immunotherapy. Further eligibility criteria
were a Karnofsky index of at least 60%, no clinical or
radiological evidence of brain metastasis, no significant alter-
ations in organ function, no endocrine disorders, and nega-
tive HIV and hepatitis serology. The protocol was approved
by the institutional review board and all patients gave written
informed consent.
Treatment
IL-2 (Ro 23-6019) and INF alfa-2a (Ro 22-8181) were pro-
vided by Hoffman-LaRoche Basle, Switzerland and Nutley,
NJ USA as a lyophilised powder in sterile vials. An intra-
venous drug delivery system (Port-A-Cath, Pharmacia AG,
Dubendorf, Switzerland) was implanted in all patients prior
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to start of treatment and IL-2 was given via a computerised
ambulatory drug delivery pump (Pharmacia Deltec CADD-1
Model 5100 HF, Pharmacia AG, Dubendorf Switzerland).
Treatment consisted in a 3 MU/m2 IL-2 as continuous
infusion on days 1-4 and 6 MU/ms INF alfa-2a subcutan-
eously on days 1 and 4, both given on alternate weeks.
Patients were given two cycles of treatment as inpatients and
continued as outpatients, if initial treatment was well toler-
ated and no grade III toxicity was observed. Patients received
novaminsulfone and paracetamol for fever, pethidine for
rigors, metoclopropamide and domperidon for nausea and
clemastin for erythema. Tumour response was assessed after
four cycles of treatment, or earlier if deemed necessary by the
investigator. Patients with stable disease or response were to
be continued for nine more cycles or up to disease progres-
sion or patients intolerance.
Toxicity and response criteria
Patients were evaluated for toxicity daily during treatment
and once during the 10 day resting period. Clinical toxicity
was assessed according to WHO classification of Grade I-IV
and tumour response was assessed according to established
criteria as CR, PR, MR and PD (WHO Handbook, 1979).
Immune modulatory parameters onperipheral blood
mononuclear cells
Immune modulatory parameters were measured as follows:
Cycle 1, 14 patients; cycle 2, eight patients; cycle 3, 12
patients; and cycle 4, six patients. Fresh peripheral blood
mononuclear cells (PMNC) were obtained from blood drawn
through a central venous line into heparinised Vacutainer
(Becton-Dickinson, Basle, Switzerland) glass tubes. A Ficoll
(Seromed, Fakola AG, Basle, Switzerland) centrifugation was
performed, cells were washed twice in Hank's balanced salt
solution (HBSS), and resuspended 1 x 106 PMNC ml-' in
HBSS. For phenotyping aliquots of 50 IAI were incubated for
30 min at room temperature in the dark with 5-20 gl of
monoclonal antibodies against the CD16 and CD56 antigens
labelled with fluorescein isothiocyanate or phycoerythrin
(Becton-Dickinson, Basle, Switzerland). After washing the
PMNC were fixed with paraformaldehyde 0.5% in Ultra-
count (Becton-Dickinson, Basle, Switzerland) resulting in a
final volume of 200Il/assay. The direct immunofluorescence
analysis was done on a EPICS Profile Analyser (Coulter
Electronics, Instrumenten-Gesellschaft, Zurich, Switzerland).
Daudi and K562 cell lines were used for the assessment of
LAK- and NK-activity, respectively. Target cells were label-
led with 100 ljCi 5"chromium 10-6 cells (Amersham, Rahn
AG, Zurich, Switzerland) according to standard procedure.
Ten thousand target cells/well were plated in a microtiter
plate (Falcon, Inotech AG, Wohlen, Switzerland) in 50 gd of
complete medium consisting (CM) of RPMI 1640 (Flow
Laboratories AG, Baar, Switzerland) supplemented with
10% foetal calf serum, 2mM L-glutamine, 50jig ml-' strep-
tomycin, 50 U ml-' penicillin and 100 U ml-' recombinant
IL-2 (F. Hoffmann-La Roche & Co, Basle Switzerland).
PMNC's were preincubated for 1 h (1 x 106 cells ml-' at
37°C, 5% C02) in CM. Appropriate 1:2 dilutions of effector
cells in 100 t CM were added to the target cells resulting in
effector/target ratios ranging from 40:1 to 1.25:1. Spon-
taneous and maximal 5"chromium-release was obtained by
the addition of 100llI cell free CM and 0.1 molar hydroch-
loride respectively. Microtiter plates were incubated for 4 h
(at 37°C, 5% CO2), the supernatants harvested with a Skat-
ron Harvester system (Tecnomara AG, Zurich, Switzerland)
and counted (2 min/probe) with a Gamma-Counter (LKB
Clinigamma, Pharmacia AG, Dubendorf, Switzerland). All
tests were done in quadruplicate. Specific tumour cell lysis
was calculated according to the formula: (experimental cpm-
spont. cpm)/(max. cpm-spont. cpm) x 100. Lytic units (LU)
per ml blood were calculated based on the E/T-ratio at the
intercept of 20% specific lysis of 5,000 target cells.
Determination ofsecondary cytokines
Five ml of venous blood was drawn on days 2-4 of cycles
1-4 in seven consecutive patients through a central venous
line into Vacutainer glass tubes (Becton-Dickinson, Basle,
Switzerland). After centrifugation with 1,000 r.p.m. for
10min, supernatant was aliquoted and stored at -20°C.
TNF alpha and INF gamma serum levels were determined by
the immunoradiometric assay kit (JRE-Medgenix AG-B6620,
Fleurus, Belgium).
Statisticalanalysis
All clinical and laboratory data were evaluated on a personal
computer using symphony spreadsheets. The paired two
sided t-test was used for comparison of immune modulatory
parameters between days 1 and 8 of cycles 1-4.
Results
Patient and treatment summary
Eight patients with melanoma and six patients with renal cell
carcinoma with a mean age of 47 (range 32-60 years) and a
mean Karnofsky index of 90% (range 80-100%) were en-
tered into the study (Table I). All patients had surgery (either nephrectomy or excision of the primary tumour or meta- stasis). Four patients received radiotherapy, three chemo-
therapy and one hormone therapy prior to entry into the study.
The 14 patients received a total of 60 cycles of treatment, of which 20 were administered as outpatients (Figure 1). The following dose adjustments were made: Patients No 4M and 2R had a 50% dose reduction after the first and the fourth cycle, respectively, because of grade III hematological and
gastrointestinal toxicity. Patient 3M had a cystic degenera- tion of a subcutaneous metastasis during treatment which required multiple aspirations of fluid and finally had to be surgically removed after three cycles of treatment. In patients SM and 6M treatment was discontinued after four cycles despite the achievement of a partial response, because of Staphylococcus aureus sepsis and patient refusal, respectively.
Toxicity
The highest grade of clinical toxicity per patient recorded
during treatment is summarised in Table II. All patients had
systemic symptoms consisting in fever, malaise and chills.
Twelve patients had a desquamative or maculopapular ery- thema. Gastrointestinal toxicity consisted in loss of appetite,
nausea, vomiting, diarrhoea and mucositis. One patient with
pre-existing paroxysmal supraventricular tachycardia had an
episode of supraventricular tachycardia requiring intravenous
verapamil. All patients had varying degrees of capillary leak
syndrome with a mean weight gain of 2.5% of entry weight, hypotension, pericardial and pleural effusion and exertional
dyspnea. A rise in serum creatinine was only observed in
patients with prior nephrectomy. CNS toxicity consisted in
nightmares and delusions. Two major infections were ob-
served with Staphylococcus aureus sepsis originating from a
central venous line. Hematological toxicity consisted in anae-
mia (four patients with Grade I, seven patients with Grade
II) and leucopenia and thrombopenia (one patient Grade
III). Five of 14 patients (36%) developed a self-limiting
autoimmune thyroiditis with a short hyperthyroid phase fol-
lowed by a prolonged hypothyroid phase. Fine needle aspira- tions, done in three patients showed a lymphohistiocytic
infiltrate with HLA-DR expression on thyroid epithelial cells
(Pichert et al., 1990). Long term toxicity was moderate with
an average weight loss of 5% of entry value and an average decrease of 10% in the Karnofsky index.EFFECTS OF IL-2 AND INF ALFA-2A 289
Table I Patient characteristics and antitumour response
Patient no!
diagnosis Age Sex Site ofmetastasis No. ofcycles Response Duration Thyroiditis
IR 45 M Subcutaneous, lung, 4 PD Yes
liver
2R 58 M Medistinal, lung, 10 NC 3 months No
soft tissue
3R 49 F Lymph nodes 4 PD No
4R 45 M Mediastinal 4 PD Yes
SR 59 M Local recurrence, lung, 4 PD No
soft tissue
6R 40 M Lung I PD died No
1M 60 M Mediastinal, lung, 4 PD No
subcutaneous
2M 43 F Lung 8 MR 2 months Yes
3M 49 F Subcutaneous 3 MR 3 months Yes
4M 24 F Local recurrence, lung 3 PD No
SM 49 M Lymph node 4 PR 7 months Yes
6M 49 F Lymph nodes, lung, 5 PR 1 month No
liver, soft tissue
7M 37 M Lung, liver, lymph 3 PD No
nodes, subcutaneous
8M 36 M Lung, subcutaneous 3 PD No
R = renal cell carcinoma, M = melanoma.
Outpatient treatment
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Figure 1 Treatment summary. Sixty cycles of IL-2 and INF
alfa-2a were given to 14 patients. Twenty cycles could be admini-
stered on an outpatient basis.
Table II Clinical toxicity: n = 14 patients
Side effect Grade I Grade II Grade III Grade IV
Constitutional 9 5
Skin 1 11 - -
GJ - 11 3
Heart 1
Lung - 6 3
Blood pressure 2 4 4
Renal 5
CNS I -
Infections - - - 2
Hematological 4 7 1
Constitutional: Fever, malaise, chills, arthralgias; Skin: Erythema
with pruritus; GJ: Nausea and vomiting; Heart: supraventricular
tachycardia; Lung: dyspnea, pleural effusion; Renal: elevated serum
creatinine; Blood pressure: hypotension; CNS: nightmares and
delusions; Infections: sepsis with staph. aureus; Hematologic: anemia,
leucopenia and thombopenia.
Antitumour effect
No responses were seen in renal cell carcinoma. Two patients
with melanoma, one with regional lymph node metastasis
and one with extensive visceral metastasis (Figure 2) had a
partial response, and two patients had a minor response
(Table I). The responses lasted from 1 to 7 months.
Figure 2 Abdominal CT scan of patient No. 6M, showing a
right mesenterial metastasis: a, before treatment and b, after five
cycles of IL-2 and INF alfa-2a.290 G. PICHERT et al.
Immune modulatory effects
Lymphocyte subset determination and measurement of NK-
and LAK-activity were done on days 1 and 8 of cycles 1-4
and INF gamma and TNF alfa serum levels were determined
on days 2-4 of cycles 1-4.
During every treatment cycle, lymphopenia was observed
on day 4 followed by a rebound lymphocytosis on day 8
(Figure 3). CD16- and CD56-positive cells as indicators for
activated lymphocytes and NK-cells increased 2.5-fold
(P<0.01) and 2-fold (P<0.01) during cycle 1, and 1.8-fold
(n.s.) or 2.6-fold respectively (P<0.05) during cycle 4 (Fig-
ure 4).
In contrast to the consistent treatment induced increase of
CD16 and CD56 pos. cells over the first four cycles; LAK-
and NK-activity increased during the first two cycles only,
plateaued during the third cycle and even decreased (n.s.)
during the fourth cycle (Figure 5).
Examination of treatment induced release of secondary
cytokines showed no significant changes in TNF alpha levels
while INF gamma levels decreased with successive cycles with
a significant difference between the first and the third cycle of
treatment (P<0.05). (Figure 6).
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Figure 4 Mean values and standard deviation of circulating a,
CD16 and b, CD56-positive cells, measured on day 1 and 8 of
cycles 1-4.
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Figure 3 Mean values and standard deviation of circulating
lymphocytes, measured on day 1, 4 and 8 of cycles 1-4.
Discussion
Our regimen of IL-2 3 MU/ms continuous infusion on days
1-4 and INF alfa-2a subcutaneously on day I and 4, given
on alternative weeks, had only moderate toxicity. The initial
concern of cumulative weight loss and decrease of Karnofsky
index by repetitive cycles of therapy was not substantiated.
The most frequent clinical toxicities were constitutional
symptoms, erythema with pruritus, nausea and vomiting, and
varying degrees of capillary leak syndrome. The first two
cycles of treatment were given in the hospital and in six of 14
patients further treatment could be administered on an out-
patient basis. None of the patients required intensive care
facilities. The only Grade IV toxicity observed was catheter
related sepsis with Staphylococcus aureus, which occurred in
two patients. Recently, it has been reported that IL-2 therapy
is associated with an increased risk of bacterial sepsis, prob-
ably due to an IL-2 induced defect of neutrophil chemotaxis
(Klempner et al., 1990). Prophylactic antibiotic therapy
might thus be of advantage in further studies using IL-2.
We have previously described a self-limiting form of auto-
immune thyroiditis with expression of HLA-DR on thyro-
cytes in patients undergoing combined IL-2 and INF alfa-2a
therapy (Pichert et al., 1990). The overall incidence of auto-
immune thyroiditis in the 14 patients reported here was 36%.
An association of thyroiditis with tumour response has been
suggested for patients treated with IL-2 and LAK-cells (At-
kins et al., 1988). Our findings of tumour response in three of
five patients with thyroiditis vs one of nine euthyroid patients
support this hypothesis. This phenomenon could be due to
the fact that HLA-DR antigen expression and auto-reactive
T-cell clones might contribute to the development of
thyroiditis as well as antitumour response.
Final data on response rates with our regimen of IL-2 and
INF alfa-2a will only be available when all data from the
multicenter trial has been analysed. In part of the study,
tumour response was only seen in patients with melanoma
(two partial and two minor responses). Using the combina-
tion of IL-2 in INF alfa-2a, we and others found little
effectivity in renal cell carcinoma (Lee et al., 1989). These
findings are in contrast to reports by Rosenberg et al., 1989,
who reported response rates of 17-41% in both melanoma
and renal cell carcinoma with escalating doses of IL-2
(3-13.5 MU/m2 per day) and INF alfa-2a (9-18 MU/ms per
day), suggesting a possible dose response relationship for the
combination of IL-2 and INF alfa-2a.
Serial measurement of immune modulatory parameters
gave unexpected findings. While there was a significant
rebound lymphocytosis with each treatment cycle, the func-
tional response of peripheral blood lymphocytes measured by
NK- and LAK-activity increased only during the first two
cycles of treatment. During the third cycle the functional
response plateaued and during the fourth cycle NK- and
LAK-activity even decreased. These findings were paralleled
by a successive decline of treatment-induced INF gamma
response, presumably the product of activated T-cells, while
the TNF alpha response, mainly a product of macrophages
was stable or did increase slightly. The decline in treatment-
induced lytic capacity of peripheral blood lymphocytes and
serum levels of INF gamma suggest that there is an exhaus-
tion of functional capacity of peripheral blood lymphocytes
with repetitive alternative weekly treatment with IL-2 and
INF alfa-2a. Earlier reports have described that repetitive
doses of human leucocyte interferon in patients with melan-
oma can lead to a decrease in NK-activity, which may be due
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Figure 5 Mean values and standard deviation of a, NK and b,
LAK activity, measured on day I and 8 of cycles 1-4.
to a therapy-acquired unresponsiveness oflymphocytes (Mal-
uish et al., 1983; Golub et al., 1982). An alternative explana-
tion for the attenuation of functional lytic response might be
the schedule dependency of the immune modulatory effects
caused by combined IL-2 and INF alfa-2a. In animal models
a synergistic effect on LAK activity has been seen when INF
was given before or after IL-2, while an inhibitory effect was
seen with concomitant administration of the two agents
a 2.5
2.0- Cycle 1 vs Cycle 3:
P<0.05
1.5
EDl. 1.0
0.5
0
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Figure 6 Induction of a, INF gamma and b, TNF alpha during
treatment. Mean serum levels with standard deviation measured
on days 2-4 of cycles 1-4.
(Tokuda et al., 1989; Brunda et al., 1986). Thus the timing of
INF alfa-2a application when given in combination with IL-2
might be important and these results should be taken into
account in designing further studies.
We thank Heidi Ernst and the nursing staff of the Division of
Oncology for their contribution to the study.
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